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ABSTRACT 
The effects of a novel, modified p-cyclodextrin (SBE4-p-CD; a variably substituted sulfobutyl 
ether with an average degree of substitution of four) on eye irritation and miotic response of an 
ophthalmically applied pilocarpine prodrug, 0,0'-dipropionyl-(l,4-xylylene) bispilocarpate, in albino 
rabbits were studied. Compared to the commercial pilocarpine eyedrop solution (163 mM, equivalent 
to 3.4% pilocarpine), 1 2 - 2 4 mM pilocarpine prodrug solutions (equivalent to 0.5 -1.0% pilocarpine, 
respectively) decreased peak miotic intensity ( I m a x ) and increased the time to reach peak ( t m a x ) , but 
did not significantly affect values for the area under the miosis versus time curves (AUC), i.e. 12 - 24 
m M pilocarpine prodrug appeared to be equivalent to 163 mM pilocarpine. Ocularly applied 12-24 
m M pilocarpine prodrug solutions, however, were more irritating than a commercial pilocarpine 
eyedrop solution. Coadministered SBE4-p-CD significantly decreased the eye irritation of the 
pilocarpine prodrug solutions. Coadministered SBE4-P-CD did not affect the miotic response of 
prodrug solution when the molar ratio of SBE4-p-CD to prodrug was low. However, increasing the 
molar ratio of SBE4-p-CD to prodrug decreased the I m a x and AUC values. The results show that eye 
irritation of the pilocarpine prodrug is prevented by levels of SBE4-P-CD that do not affect the 
apparent ocular absorption of the prodrug. 
INTRODUCTION 
Pilocarpine is a widely used drug for controlling the elevated intraocular pressure associated 
with glaucoma. However, duration of action for ophthalmic pilocarpine is short and its ocular 
bioavailability is only 0.1-3% of the instilled pilocarpine dose (1-3). Thus, the prodrug technique has 
been applied to improve the ocular delivery of pilocarpine (4-6). 0,0'-Dipropionyl-(l,4-xylylene) 
bispilocarpate (Fig. la) is a dimeric pilocarpine double prodrug which releases pilocarpine via 
enzymatic and chemical hydrolysis in the eye. Due to its higher lipophilicity, the corneal permeability 
coefficient for O,0'-dipropionyl-(l,4-xylylene) bispilocarpate is several times higher than that for 
pilocarpine (7) and ocular absorption of pilocarpine is increased by this pilocarpine prodrug (8). 
Unfortunately, preliminary results suggest that the clinical acceptability of 0,0'-dipropionyl-(l,4-
xylylene) bispilocarpate may be mosdy limited by the eye irritation induced by the pilocarpine prodrug 
solut ion. For stability and solubility reasons, the pH of 0,0'~dipropionyl-(l,4-xylylene) 
bispilocarpate eyedrops cannot be higher than 5.0 (6). Acidic eyedrop solutions may result in 
decreased ocular bioavailability due to the resulting induced lacrimation and lower corneal permeability 
(9) . 
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Cyclodextrins (CDs) are a group of homologous cyclic oligosaccharides consisting of six, 
seven or eight glucose units called a-, (3- or 7-cyclodextrin, respectively. CDs are well-known for their 
ability to form inclusion complexes with a wide variety of hydrophobic drugs. Inclusion complex 
formation between drug and CD may improve drug solubility and/or stability (10-12) as well as 
bioavailability of the drug (13, 14). The use of CDs has been studied extensively in parenteral, oral, 
rectal and dermal formulations (15-17), however, the effects of CDs on ocular delivery of topically 
applied drugs are poorly understood. It has been reported that coadministration of hydroxypropyl-p. 
CD increases the intraocular pressure lowering effect of prostaglandins (18) and ocular absorption of 
dexamethasone, dexamethasone acetate (19), and pilocarpine (20). 
SBE4-P-CD and SBE7-p-CD (average degree of butylsulfonate substitute of seven) have been 
developed with the purpose of improving the toxicity, aqueous solubility and subsequent 
pharmaceutical usefulness of (3-CD (21). In SBE-p-CD, the sulfonate group (as its sodium salt) is 
spaced from the cyclodextrin cavity by a butyl chain to ensure that the new substituents do not interfere 
with the inclusion process. The degree of substitution indicates the number of sulfobutyl moieties per 
cyclodextrin molecule. The solubility enhancements observed with SBE4-p-CD (Fig. lb) are 
comparable to or higher than those observed with hydroxypropyl-p-CD (22, 23). 
The purpose of this study was to evaluate the effect of SBE4-p-CD on the ocular absorption, as 
indicated by miosis, and eye irritation of bispilocarpic acid diester prodrug. This study demonstrates 
the usefulness of this new p-cyclodextrin derivative as an adjuvant in lipophilic prodrug eyedrop 
solutions. 
MATERIALS AND METHODS 
Solution Preparation 
The synthesis and identification procedures for pilocarpine prodrug, O,0'-dipropionyl-(l,4-
xylylene) bispilocarpate as a fumarate salt and for SBE4~p-CD (average mw = 1725.9) have been 
described previously (23-25). The chemical structures for 0,0 ' -dipropionyl-( l ,4-xylylene) 
bispilocarpate and SBE4-p-CD are shown in Fig. 1. 
a b 
FIGURE 1. The Chemical Structure of 0,0'-Dipropionyl (1,4-Xylylene) Bispilocarpate (a) and 
Tetra-Sulfobutyl Ether p-Cyclodextrin (SBE4~p-CD) (b). 
Pilocarpine in eyedrop formulation (Oftan Pilocarpin®, 163 mM) was purchased from Leiras 
Oy (Finland). Pilocarpine eyedrops (pH = 5.0) contained pilocarpine hydrochloride 40 mg/mL and 
96 
benzalkonium chloride 40 \ig/mL. Pilocarpine prodrug and pilocarpine prodrug containing SBE4-p-
CD solutions were prepared by dissolving the required amount of pilocarpine prodrug and SBE4-p-CD 
in 5.0 mL of double distilled water, and pH of the solutions was adjusted to 5.0 or 6.0 with sodium 
hydroxide. The solutions were made isotonic with sodium chloride. The pilocarpine prodrug 
solutions were prepared equivalent to a 0.5% and a 1.0% pilocarpine solution. 
The control solutions were 0.9% sodium chloride solution (Sigma Chemical Co. St. Louis, 
M O , pH was adjusted to 5.0 with hydrochloride acid) and 10% (58 mM) SBE4-p-CD solution (pH 
5.0). The latter solution was prepared as described above but no prodrug was dissolved in solution. 
Animals 
The experimental animals used in this study were adult male New Zealand White albino rabbits 
weighing between 2.8 - 3.6 kg. The rabbits were housed singly in cages under standard laboratory 
conditions: 12 h dark/12 h light cycle. The rabbits were given food and water ad libitum. The 
experiments conformed to the ARVO Resolution on the use of animals in research. 
Evaluation of Eye Irritation 
To estimate the discomfort caused by an instilled eyedrop, the extent of eyelid closure (closed 
or half-closed) following immediately after unilateral eyedrop administration (25 |iL) was observed 
and recorded. Once the rabbit opened its eye fully, the eyelid closure behavior was no longer recorded. 
The amount of mucoidal discharge at 0.25 and 1 h after eyedrop administration was also recorded. 
Mucoidal discharge was scored from 0 to 2 as follows: 0 = normal, no lacrimation, 1 = slight 
discharge (any amount different from normal, clear discharge) and 2 = strong discharge (moisten the 
lids and hairs just adjacent to the lids, milk-like discharge). Eye irritation was always evaluated by the 
same operator who did not know composition of an instilled solution. At least 72 h wash-out time 
was allowed for each rabbit between dosings. 
Miotic Response 
To perform each evaluation, the rabbit was placed in a plastic restraining box located in a quiet 
room with constant light condition. The rabbit was kept in that environment for 1 h before eyedrop 
administration in order to acclimatize it to the environment. The test solution (25 |LLL) was instilled on 
the upper corneoscleral limbus. During the instillation the upper eyelid was slightly pulled away from 
the globe. All solutions were administered into the right eye while the left eye remained untreated. To 
measure the pupil diameter, the eyes were photographed from a constant distance at 0.5, 0.25 and 0 h 
before and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5 and 6 h after drug administration. The 
negatives were enlarged with a microfilm reflector and the pupillary diameters were determined as a 
mean of horizontal and vertical diameters. Pupillary diameter at the time of eyedrop administration (at 
0 h) was used as a baseline pupillary diameter. The lighting conditions in laboratory gave a baseline 
pupillary diameter in the range of 6.4 - 7.9 mm. The studies were set up in a 5 x 5 or a 6 x 6 masked 
cress-over design. At least 72 h wash-out time was allowed for each rabbit between dosings. 
Analysis of Data 
The magnitude of the miotic responses (%) was calculated as ( ( P D 0 - PDt) /PD 0 ) x 100%, 
where P D 0 is a baseline pupillary diameter and PDt is pupillary diameter at the time point. For each 
rabbit at each time point, individual miotic response values for 0.9% NaCl solution were subtracted 
from the miotic response values for drug solution and then the following pharmacokinetic parameters 
were calculated. Areas under the miotic response versus time curves (AUC 0_6 h) were calculated using 
the trapezoidal method (26), and the value for miotic response was assumed to be equal to zero if it 
was negative after subtraction of the value for 0.9% NaCl solution at the same time point. Peak miosis 
intensity ( I m a x ) and its time ( t m a x ) were determined from the actual data points. The duration of 
response was determined from miosis versus time profiles by calculating the total period of time when 
miosis was equal or more than 30%, 10% or 5%. All the values are expressed as mean ± S.E. 
(standard error). A one-factor analysis of variance (ANOVA for repeated measurements) was used to 
test the statistical significance of differences between groups; significance in the differences in the 




Eyelid closure data are shown in Fig. 2 (eye closed or half-closed) and in Table 1 (sum of eye 
lid closure). Compared to a commercial pilocarpine eyedrop solution, Oftan Pilocarpin® (163 mM, 
3.4% pilocarpine), duration of eyelid closure after administration of 24 mM prodrug solution 
(equivalent to a 1.0 % pilocarpine solution) was significantly longer (p<0.05, by Fisher's PLSD test). 
The rabbits kept their eyes closed or half-closed (sum of eye lid closure) for 1.2 ± 0.3 min, for 2.1 ± 
0.6 min and for 11.5 ± 5.6 min after ocular administration of a 163 mM commercial pilocarpine 
solution, 12 mM prodrug solution and 24 mM prodrug solution, respectively (Table 1). Prodrug 
solutions caused significantly stronger (p<0.05, by Fisher's PLSD test) ocular discharge at 0.25 h 
(scores were 0.8 ± 0.3 for 24 mM prodrug and 0.3 ± 0.2 for 12 mM prodrug) and at 1 h (scores were 
1.8 ± 0.2 for 24 mM prodrug and 0.7 ± 0.3 for 12 mM prodrug) after ocular administration than 163 
mM commercial pilocarpine solution (0.0 ± 0.0). 
TABLE 1 
Miotic Activity Parameters and Duration of Eyelid Closure After Ocular Administration of 25 \iL of 
Pilocarpine or Pilocarpine Prodrug (0,0'-Dipropionyl-( 1,4-Xylylene) Bispilocarpate) in the Presence 
or Absence of Tetra-Sulfobutyl Ether p-Cyclodextrin (SBE4-p~CD) in Albino Rabbits (mean ± S.E. n 
= 5-6). 
Solution pH Peak t ime a 
(min) 
I b 1 max 
(%) 
Eye lid closure0 
(min) 
Oftan Pilocarpin® (163 mM, 
3.4% ) 
5.0 21 ± 3 36.1 ± 1.9 1.2 ± 0 . 3 
12 mM Pilocarpine Prodrug 
(equivalent to 0.5% pilocarpine) 5.0 132 ± 2 8 * 17.5 ± 2.2* 2.1 ± 0.6 
12 mM Pilocarpine Prodrug + 
2.5% (14.5 mM) SBE4-p-CD 5.0 114 ± 3 5 * 16.9 ± 2.4* 1.0 ± 0 . 4 
12 mM Pilocarpine Prodrug + 
10 % (58 mM) SBE4-P-CD 5.0 150 ± 2 1 * 12.5 ± 1.2* 0.5 ± 0.3* 
24 mM Pilocarpine Prodrug 
(equivalent to 1% Pilocarpine) 5.0 118 ± 2 3 * 21.9 ± 4 . 8 * 11.5 ±5 .6* 
24 mM Pilocarpine Prodrug + 
5% (29 mM) SBE4-P-CD 5.0 103 ± 2 7 * 20.3 ± 2 . 1 * 1.5 ± 0 . 3 * 
24 mM Pilocarpine Prodrug + 
10 % (58 mM) SBE4-P-CD 5.0 118 ± 2 3 * 16.8 ± 1.5* 0.8 ± 0 . 2 # 
24 mM Pilocarpine Prodrug + 
5% (29 mM) SBE4-P-CD 6.0 123 ± 24* 22.5 ± 1.6* 1.9 ± 0 . 5 # 
24 mM Pilocarpine Prodrug+ 
10 % (58 mM) SBE4-P-CD 6.0 135 ± 2 3 * 17.7 ± 2.9* 0.8 ± 0 . 3 # 
a Time to reach I m a x , bMaximum miotic effect, cPeriod of time when eye was closed or half-closed. 
* Significantly different from the value for Oftan Pilocarpin® (163 mM) (p<0.05, by Fisher's PLSD 
test). 
# Significantly different from the value for 24 mM prodrug (p<0.05, by Fisher's PLSD test), 
t Significantly different from the value for 12 mM prodrug (p<0.05, by Fisher's PLSD test). 
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The duration of eyelid closure after ocular administration of isotonic, non-drug containing 
SBE4-P-CD solution (10 % w/v. 58 mM) was similar to that for 0.9% sodium chloride solution (Fig. 
2). The duration of eyelid closure after topical administration of 24 mM pilocarpine prodrug solution 
was decreased significantly (p< 0.05, by Fisher's PLSD test) by SBE4-|3-CD coadministration (29-58 
mM) (Table 1, Fig. 2). The rabbits kept their eyes closed or half-closed (sum of eyelid closure) for 
0.8 -1.9 min after ocular administration of the pilocarpine prodrug (24 mM) containing SBE4-p-CD 
(29 - 58 mM) solutions. In addition, discharge observed at 0.25 and Ih after ocular administration of 
12 mM and 24 mM pilocarpine prodrug solutions was eliminated by SBE4-p-CD coadministration. 
These results show that eye irritation caused by 12 - 24 mM pilocarpine prodrug solution that contains 
14.5 - 58 mM of SBE4-f3-CD is comparable to the eye irritation caused by 163 mM commercial 
pilocarpine eyedrops (Fig. 2, Table 1). Increasing the pH of pilocarpine prodrug containing SBE4-p-
CD solution from 5.0 to 6.0 did not affect the eye irritation due to solution (Fig. 2, Table 1). 
Time (min) 
FIGURE 2. Duration of Eyelid Closure after Ocular Administration of 25 (iL of Pilocarpine (Oftan 
Pilocarpin®) or Pilocarpine Prodrug (O f O f -DipropionyH 1,4-Xylylene) Bispilocarpate) (PRO) in the 
Presence or Absence of SBE4-{J-CD (SBE) in Albino Rabbits (mean ± S.E., n = 5-6). 
The results for miosis studies are summarized in Tables 1 and 2. Miosis versus time profiles 
for 0.9% sodium chloride and isotonic 58 mM SBE4~p~CD solutions were similar (Fig. 3). 
Time (min) 
FIGURE 3, Change in Pupillary Diameter after Ocular Administration of 25 \ih of (X9% NaCl ( • ) or 
58 mM (10% w/v) SBE4-p-CD ( • ) in Albino Rabbits. Values are means ± S.E. (n = 5-6), 
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Oftan Pilocarpin; 3.4 % 
58 mM SBE, pH 5.0 
0.9% NaCl, pH 5.0 
12 mM Pro (= 0.5% Pilo). pH 5.0 
12 mM Pro + 14.5 mM SBE, pH 5.0 
12 mM Pro + 29 mM SBE, pH 5.0 
24 mM Pro (= 1.0% Pilo), pH 5.0 
24 mM Pro + 29 mM SBE, pH 5.0 
24 mM Pro + 58 mM SBE, pH 5.0 
24 mM Pro + 29 mM SBE, pH 6.0 
24 mM Pro + 58 mM SBE, pH 6.0 
Compared with 163 mM commercial pilocarpine eyedrops (3.4% pilocarpine), 12 and 24 m M 
prodrug solutions (equivalent to a 0.5% and a 1.0 % pilocarpine solution, respectively) decreased peak 
miotic intensity ( I m a x ) and increased the time to reach peak ( t ^ ) significantly (p< 0.05, by Fisher's 
PLSD test). However, 12 and 24 mM prodrug solutions had values for areas under the miotic 
response versus time curves (AUC0.<5h) and the period of time when miotic response was equal or 
more than 5% or 10% comparable to the 163 mM pilocarpine solution (Table 2, Fig. 4 ) . 
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FIGURE 4. Change in Pupillary Diameter after Ocular Administration of 25 [iL of Pilocarpine (163 
mM, 3.4%) ( • ) or Pilocarpine Prodrug (24 mM, Equivalent to 1.0% Pilocarpine (O) and 12 m M , 
Equivalent to 0.5% Pilocarpine ( • ) ) Solutions at pH 5.0 in Albino Rabbits. Values are means ± S ,R; 
n = 5 - 6. 
The miotic response of 12 mM pilocarpine prodrug and pilocarpine prodrug (12 m M ) 
containing SBE4-P-CD (2.5% (w/v), 14.5 mM) solutions was similar as indicated by similar t m a x , 
W A U C 0 - 6 h v a l u e s (Tables 1 and 2). Compared to a 12 mM prodrug solution, prodrug (12 
mM) containing SBE4-p-CD (10% (w/v), 58 mM) solution did not significantly affect and I m a x 
values but significantly decreased A U C Q . ^ V A L U E m & t h t period of time when miotic response w a s 
more than 10% (p< 0.05, by Fisher's PLSD test) (Tables 1 and 2, Fig. 5). 
FIGURE 5. Change i n Pupillary Diameter after Ocular Administration of 25 uL of Pilocarpine 
c n ^ r ! t A }i } » ™ o c a r P i n e P r o d ™ g (12 mM) Containing SBE4-p-CD (58 mM, 10% w/v) 
(O) Solution in Albino Rabbits. Values are means ± S E • n = 5 
1 0 0 
In the case of the 24 mM pilocarpine prodrug solutions (pH 5.0 - 6.0), coadministration of 29 
- 58 mM of SBE4-p-CD in solutions did not significantly change the miotic activity parameters ( t m a x , 
I m a x , AUC0„6h> duration time) (Tables 1 and 2). However, increasing the concentration of SBE4-p-
CD in 24 mM pilocarpine prodrug solution did tend to reduce the miotic response of the solution. 
TABLE 2 
Miotic Activity Parameters after Administration of 25 |llL of Pilocarpine or Pilocarpine Prodrug (0 ,0 ' -
Dipropionyl-(l,4-Xylylene) Bispilocarpate) in the Presence or Absence of Tetra-Sulfobutyl Ether p-
Cyclodextrin (SBE4-p-CD) in Albino Rabbits (mean ± S.E., n = 5-6). 
Solution pH 
5 % a 
(min) 
Duration 
1 0 % b 
(min) 
3 0 % c 
(min) 
A U C Q . 6 h d 
(% x h) 
Oftan Pilocarpin® 
(163 mM, 3.4 % ) 
5.0 206 ± 20 143 ± 13 27 ± 7 66.5 ± 4.4 
12 mM Prodrug 
(resp. 0.5% Pilocarpine) 5.0 219 + 22 124 + 41 0 46.3 ± 9.0 
12 mM Prodrug + 2.5% 
(14.5 mM) SBE4-P-CD 5.0 254 ± 36 149 ± 49 0 52.4 ± 11.7 
12 mM Prodrug + 
1 0 % ( 5 8 m M ) SBE4-P-CD 5.0 1 5 4 ± 2 6 # 34 + 20*+ # 0 27.2 ±4 .5** 
24 mM Prodrug 
(Resp. 1% Pilocarpine) 5.0 243 ± 34 161+49 31 ± 2 5 69.0 ± 23.4 
24 mM Prodrug + 
5% (29 mM) SBE4-P-CD 5.0 263 ± 35 169 ± 3 8 0 59.1 ± 9 .9 
24 mM Prodrug + 
10 % (58 mM) SBE4-P-CD 5.0 2 3 1 + 2 5 101 ± 2 2 0 43.2 ± 4.9 
24 mM Prodrug + 
5% (29 mM) SBE4-P-CD 6.0 288 ± 26* 184 ± 2 1 0 67.1 ± 6 . 4 
24 mM Prodrug + 
10 % (58 mM) SBE4-P-CD 6.0 214 ± 3 8 98 ± 3 4 0 43.9 ± 9.4 
a " c Time period when miosis was > 5 % a , > 1 0 % b and > 30% c ; d Area under miosis versus time curve. 
* Significantly different from the value for Oftan Pilocarpin® (163 mM) (p<0.05, by Fisher's PLSD 
test). 
i Significantly different from the value for 12 mM prodrug (p<0.05, by Fisher's PLSD test). 
# Significantly different from the value for 12 mM prodrug + 2.5% SBE4-p-CD (p<0.05, by 
Fisher's PLSD test). 
Coadministered SBE4-p-CD increased the aqueous solubility of the prodrug as indicated by the 
following results: For solubility reasons, it was not possible to prepare 24 mM pilocarpine prodrug 
solution at pH values higher than 5.0. However, 24 mM pilocarpine prodrug solutions could be made 
at pH 6.0 by coadministering SBE4-P-CD in the solution. Increasing the pH of the prodrug (24 mM) 
containing SBE4-P-CD (29-58 mM) solutions from 5.0 to 6.0 did not affect miotic activity parameters 
of the solutions significantly (Tables 1 and 2). 
The results show that the eye irritation of ophthalmic pilocarpine prodrug, 0,0'-dipropionyl-
(1,4-xylylene) bispilocarpate, is prevented by levels of SBE4-p-CD (Fig. 6a) that do not affect the 
apparent ocular delivery of the prodrug in rabbits (Fig. 6b). 
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Oftan Pilocarpin; 3.4 % 
24 mM Pro (= 1.0% Pilo), pH 5.0 
24 mM Pro + 29 mM SBE, pH 6.0 
0 1 2 3 4 5 6 7 8 9 10 11 12 13 
Time (min) 
FIGURE 6a. Duration of Eyelid Closure after Ocular Administration of 25 | iL of Pilocarpine (Oftan 
Pilocarpin®; 163 mM), 24 mM Pilocarpine Prodrug (pH = 5.0) and 24 mM Pilocarpine Prodrug 
Containing 29 mM (5% w/v) SBE4-P-CD (pH = 6.0) Solution in Albino Rabbits. Values are means ± 
S.E.; n = 6. 
FIGURE 6b. Change in Pupillary Diameter after Ocular Administration of 25 |iL of 24 mM 
Pilocarpine Prodrug Solution (pH 5.0) (O) or 24 mM Pilocarpine Prodrug with 29 mM (5% w/v) 
SBE4-P-CD Solution (pH 6.0) ( • ) in Albino Rabbits. Values are means ± S.E.; n = 6. 
D I S C U S S I O N 
Eye Irritation 
SBE4-p~CD itself was not irritating when given topically in rabbit eyes and consequently, it 
might be a suitable adjuvant for ophthalmic drug preparations. Trie maximum strength of pilocarpine 
eyedrops that are in common use among glaucoma patients is 163 mM (equivalent to 4% pilocarpine 
hydrochloride). Consequently, the eye irritation of a topically applied pilocarpine prodrug should not 
be more than that seen with 163 mM pilocarpine eyedrops. In the present study, however, a new 
pilocarpine prodrug (24 mM) applied topically caused significantly more eye irritation than 163 mM 
pilocarpine eyedrops. This might be due to a rapid absorption of lipophilic prodrug molecules into the 
lipophilic corneal epithelium and/or precipitation of prodrug molecules in the precorneal area and/or 
direct and specific toxicity of this pilocarpine prodrug molecule. Due to the rapid absorption of 
lipophilic pilocarpine prodrug into the corneal epithelium, temporary high and irritating prodrug 
concentrations may occur in the epithelium after ocular administration. 
Increased aqueous solubility of the pilocarpine prodrug in the presence of SBE4-p-CD 
suggests that SBE4-p-CD did indeed interact with the pilocarpine prodrug studied. In general, 
cyclodextrins are well-known for their ability to form inclusion complexes with hydrophobic drugs 
(15). Drug/p-CD inclusion complex and p-CD itself do not penetrate across biological membranes 
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largely due to the hydrophilic character of CDs (27,28). Thus, drug/p-CD complexes must dissociate 
before drug absorption. Based on these findings, we assume that the pilocarpine prodrug must be 
released from pilocarpine prodrug/SBE4«p-CD inclusion complexes before ocular delivery of the 
prodrug can occur. Consequently, coadministered SBE4-P-CD may act to temporarily slow the ocular 
absorption rate of the pilocarpine prodrug. As a result, coadministered SBE4-p-CD decreased the high 
initial concentration of the pilocarpine prodrug in the corneal epithelium and thus, decreased eye 
irritation (Fig. 2). 
Rye irritation observed after topical administration of pilocarpine prodrug solutions might also 
be due to the precipitation of the pilocarpine prodrug in the precorneal fluids. It is known that the pH 
of instilled solutions will he readjusted to the normal tear pH (7.4 ± 0.1) within a few minutes after 
administration of an acidic unbuffered eyedrop solution in the rabbit eye (29. 30). The aqueous 
solubility of the studied pilocarpine prodrug is very poor at pH 7 « 1 mg/mL) (6). Thus, due to an 
increase in pH of solution, precipitation of topically applied pilocarpine prodrug molecules at the 
precorneal area may occur causing eye irritation. The increased aqueous solubility of the pilocarpine 
prodrug in the presence of SBE4~p-CD may hinder the precipitation of this prodrug in the precorneal 
fluids and subsequently decrease the eye irritation. The pH of the pilocarpine prodrug/SBE4-p-CD 
combinations was increased from 5.0 to 6.0 in order to reduce any eye irritation of solutions 
associated with the use of low pH value. However, eye irritation of the pilocarpine prodrug/SBE4-p-
CI) combination was not affected by the pi I change. This result suggests that the principal reason for 
eye irritation following administration of the combination solutions is the pilocarpine prodrug molecule 
itself, not necessarily the acidic pH of the solution. 
Miotic response is widely used as an indication of biological response for ophthalmic 
pilocarpine (31. 32). Although the precise relationship between pilocarpine induced miosis and its 
ability to lower intraocular pressure has not been established in rabbits, it has been shown that a linear 
relationship exits between the area under the miosis versus time curve and aqueous humor 
concentration of pilocarpine in albino rabbits (33). This is true when pilocarpine concentration in 
eyedrops is not high enough to cause the absolute maximum miotic response in rabbit eye. Ocularly 
applied non-drug containing SBE4-p-CD solution did not cause miosis or mydriasis (Fig*. 3) and thus, 
the effect of coadministered SBK4-P-CD on ocular absorption of pilocarpine prodrug was possible to 
evaluate by the miotic method. 
Pilocarpine prodrugs have been developed in order to improve the ocular delivery of 
pilocarpine, e.g. to eliminate the high peak concentrations of pilocarpine in the eye and to prolong its 
duration of action (4-6). In the present study, administration of 14.3% (1/7) of the pilocarpine dose as 
a prodrug ((),()* -dtproptonyM 1,4-xylylene) bispilocarpate) decreased the peak miotic intensity of the 
solution and increased the time to reach the peak, but did not significantly affect values for the area 
under the miosis versus time curves (AUC). i.e. 12 mM pilocarpine prodrug (equivalent to 0.5% 
pilocarpine) appeared to be equivalent to 163 mM (3.4%) pilocarpine. The increased bioavailability of 
pilocarpine (log P = 0.01, octanol/buffer, pH 7.4) when given as the studied prodrug was presumably 
due to the higher lipophilicity of the prodrug (log P = 4.08. octanol/buffer, pH 7.4, (6)). The optimum 
apparent partition coefficient (log P octanol/buffer, pH 7,4) for corneal absorption of a stable drug is 
2-3 (34-36). In the case of double prodrugs, it is more complicated to estimate the optimal log P value 
for corneal permeability because their corneal permeability is dependent both on the lipophilicity of the 
double prodrug/prodrug/parent drug and on the conversion rate of double prodrug/prodrug to the 
parent drug. The corneal uptake studies suggest that the largest ocular bioavailability for pilocarpine 
double prodrugs may be obtained with a larger value of log P (octanol/buffer, pH 7.4) than 2-3 (7, 
37). 
The effect of coadministered SBE4-P-CD on the miotic response of the pilocarpine prodrug 
was dependent on the molar ratio of the cyclodextrin to the prodrug. Coadministered SBE4-p-CD did 
not affect the miotic response of pilocarpine prodrug solution when the molar ratio of cyclodextrin to 
prodrug was low enough. This result suggests that the rate of dissociation of pilocarpine 
prodrug/SBE4»p-CD complex in the precorneal area was faster than the rate of ocular absorption of 
pilocarpine prodrug. However, coadministration of !SBE4-p~CD at high concentrations reduced the 
miotic response of the pilocarpine prodrug solution. As discussed earlier, it is generally assumed that 
only free drug, not drug/cyclodextrin complex, can penetrate across biological membranes (27, 28, 
38). Consequently, substantial complexation of pilocarpine prodrug with SBE4-p-CD can be expected 
to decrease the ocular delivery of pilocarpine prodrug due to a significant decrease in traction of free 
pilocarpine prodrug in solution. Besides, in contrast to oral or parenteral administration, a significant 
decrease in the fraction of complexed prodrug due to dilution does not occur in the precorneal area 
after ocular administration because tear fluid volume is very small (»7 |iL). 
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The pilocarpine prodrug studied is a base with p K a of 6.7 (6). As the pH of this pilocarpine 
nrodrus solution is increased from 5.0 to 6.0, the fraction of unionized prodrug increases. Because 
the unionized form of pilocarpine is absorbed across the cornea more easily than its ionized form (39), 
ocular absorption of the studied pilocarpine prodrug can be expected to increase by increasing pH of 
the prodrug solution. However, changes in the pH of the pilocarpine prodrug/SBE4-p-CD 
combination did not affect the miotic response of the solution significantly. This result can be 
attributed to two factors. Due to the low buffer capacity of the solutions, both pH 5.0 and pH 6.0 
solutions were probably readjusted to physiological pH within few minutes after ocular administration 
(29 30) On the other hand, the stability constant of the prodrug with SBE4-p-CD may be larger at pH 
6 o'than at pH 5 0 due to increased fraction of unionized prodrug in pH 6.0 solution (40) and thus, 
dissociation of the pilocarpine prodrug/SBE4-(3-CD complex may be weaker lor the pH 6.0 solution. 
This could compensate for the positive effect of increased fraction of unionized prodrug in pH 6.0 
solution on miotic response. . 
It can be concluded that eye irritation due to the ophthalmic pilocarpine prodrug, O,0'~ 
dipropionyl~(l 4-xylylene) bispilocarpate, can be prevented by levels of SBE4-|3-CD that do not affect 
the apparent ocular absorption of the pilocarpine prodrug. SBE4-P-CD was not irritating when given 
topically in the eyes of rabbits; and based on the preliminary results (22), systemically administered 
SBE4-P-CD seems to be safer than a parent p-cyclodextrin and some other p-cyclodextrin derivatives. 
Consequently, SBE4-P-CD may be a useful adjuvant in the development of ophthalmic formulations. 
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